Trial Profile
An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2020
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 23 Sep 2020 Results assessing efficacy of a combination of buparlisib and cetuximab on the patient-derived xenografts models published in the British Journal of Cancer
- 05 Apr 2017 Status changed from recruiting to completed, based on the results presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research